Atezolizumab plus bevacizumab in advanced hepatocellular carcinoma after treatment failure with multikinase inhibitors.
Fiche publication
Date publication
avril 2023
Journal
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre, Pr MANFREDI Sylvain
Tous les auteurs :
Haghnejad V, Muller M, Blaise L, Gerolami R, Bouattour M, Assenat E, Manfredi S, Peron JM, Burcheri-Curatolo A, Lopez A, Ressiot E, Nahon P, Bronowicki JP
Lien Pubmed
Résumé
Data on the effectiveness of atezolizumab plus bevacizumab (atezo-bev) after failure of multikinase inhibitor (MKI) therapy in patients with advanced hepatocellular carcinoma are scarce.
Mots clés
Atezolizumab plus bevacizumab, Hepatocellular carcinoma, Liver cancer, Tyrosine kinase inhibitors
Référence
Dig Liver Dis. 2023 04 3;: